Health & bio

FDA Advisory Panel Reviews Camizestrant and Truqap on April 30

Proceedings for ER+/HER2- early breast cancer and PTEN-deficient metastatic hormone-sensitive prostate cancer underway.

Primary sources · 1
FDA Tracker
← View the full 2026-05-02 (Sat) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →